Home › NDC Lookup › RxCUI directory › RxCUI 2387343

Tafasitamab-cxix 200 MG Injection [Monjuvi] — RxCUI 2387343

RxNorm drug concept · Semantic branded drug
RxCUI 2387343 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2387343
Official nameTafasitamab-cxix 200 MG Injection [Monjuvi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMonjuvi 200 MG Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)103 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tafasitamab-cxix Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Monjuvi is a targeted antibody therapy given through an IV. It's designed to find and attack cancer cells in certain types of lymphoma — specifically diffuse large B-cell lymphoma...
  • What exactly is Monjuvi, and why has my doctor prescribed it for me?
  • At the start, you'll come in quite often — for DLBCL, there are several infusions in the first few weeks. As treatment goes on, the schedule spreads out to twice a month. Each infu...
  • How often will I need to come in for infusions, and how long does each one take?
📖 Read our full Tafasitamab-cxix Injection guide →

🕸️ Concept Web — How Tafasitamab-cxix 200 MG Injection [Monjuvi] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tafasitamab-cxix 200 MG Injection [Monjuvi] RxCUI 2387343

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Tafasitamab 2387211
    • Tafasitamab-cxix 2387334
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Monjuvi 2387339
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tafasitamab Injection 2387337
    • Tafasitamab-cxix Injection 2647677
    • Tafasitamab Injectable Product 2387336
    • Tafasitamab-cxix Injectable Product 2662646
    • Tafasitamab Injection [Monjuvi] 2387341
    • Tafasitamab-cxix Injection [Monjuvi] 2654618
    • Monjuvi Injectable Product 2387342
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tafasitamab-cxix 200 MG Injection SCD · 2387338
  • Tafasitamab-cxix 200 MG SCDC · 2387335
  • Tafasitamab Injection SCDF · 2387337
  • Tafasitamab-cxix Injection SCDFP · 2647677
  • Tafasitamab Injectable Product SCDG · 2387336
  • Tafasitamab-cxix Injectable Product SCDGP · 2662646

Brand-Name Concepts

  • Tafasitamab-cxix 200 MG [Monjuvi] SBDC · 2387340
  • Tafasitamab Injection [Monjuvi] SBDF · 2387341
  • Tafasitamab-cxix Injection [Monjuvi] SBDFP · 2654618
  • Monjuvi Injectable Product SBDG · 2387342
  • Monjuvi BN · 2387339

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2387343 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50881-0013-03 1 VIAL in 1 CARTON (50881-013-03) / 5 mL in 1 VIAL MONJUVI Incyte Corporation 2020-08-05
73535-0208-01 1 VIAL in 1 CARTON (73535-208-01) / 5 mL in 1 VIAL MONJUVI Incyte Corporation 2020-08-05
Observed labelers: Incyte Corporation (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9349 Inj., tafasitamab-cxix 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.